Status:

COMPLETED

Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden

Lead Sponsor:

M.D. Anderson Cancer Center

Conditions:

Multiple Myeloma

Primary Amyloidosis

Eligibility:

All Genders

60+ years

Phase:

PHASE2

Brief Summary

The goal of this clinical research study is to learn whether higher doses of stem cells can help to decrease the symptoms that occur after melphalan. Another goal of the study is to see how the dose o...

Detailed Description

Stem cells are found in the bone marrow and bloodstream, and they rebuild blood, bone marrow, and the immune system. This study uses autologous stem cells, which are stem cells collected from your own...

Eligibility Criteria

Inclusion

  • Patients with multiple myeloma over the age of 60 in any of the following disease categories: a) Primary refractory disease b) Consolidation of a first partial or complete remission. OR
  • Patients with primary amyloidosis.
  • Zubrod PS of \<2 or Karnofsky \>/= 70.
  • Left ventricular ejection fraction \>/= 40%. No uncontrolled arrhythmias or symptomatic cardiac disease.
  • Forced expiratory volume at one second (FEV1), forced vital capacity (FVC) and diffusion capacity of lung for carbon monoxide (DLCO) \>/= 40%. No symptomatic pulmonary disease.
  • Serum bilirubin \</= 2 X upper limit of normal, serum glutamate pyruvate transaminase (SGPT) \</= 4 X upper limit of normal. No evidence of chronic active hepatitis or cirrhosis. No effusion or ascites \>1L prior to drainage.
  • HIV-negative.
  • Patient is not pregnant.
  • Patient or guardian able to sign informed consent.
  • Have greater than or equal to 10 x 10 e 6 CD34+ cells per kg of autologous stem cells cryopreserved for stem cell transplantation, procured with 5 or fewer apheresis collections.

Exclusion

  • 1\) Patients unable to perform MDASI assessments due to language or cultural barriers.

Key Trial Info

Start Date :

March 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 1 2016

Estimated Enrollment :

80 Patients enrolled

Trial Details

Trial ID

NCT00651937

Start Date

March 1 2008

End Date

January 1 2016

Last Update

January 14 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Texas MD Anderson Cancer Center

Houston, Texas, United States, 77030